MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD

Reuters

2025/10/30

MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD

Mind Medicine (MindMed) Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579515632"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579515632\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579515632?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579515632","market":"us","top_or_hot":-1,"title":"MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 08:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL1TlVHF:1","article_id":"2579515632","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579515632","pubTimestamp":1761782485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder  and major depressive disorder . The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4547":"WSB热门概念"},"translate_title":"MindMed推出新的公司演示文稿，强调后期管道以及对GAD和MDD的战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    \n\nMind Medicine (MindMed) Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}